Promega Tailored R&D Solutions (TRS) services are now listed on Scientist.com and Science Exchange. These platforms streamline access to customized Promega technologies and R&D collaboration. TRS is a collaborative partner that works with drug discovery researchers to build bespoke solutions to unique problems and perform screening services. MADISON, Wis.–(BUSINESS WIRE)–Promega Tailored R&D Solutions (TRS) … [Read more…]
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile The launch strengthens Zambon’s presence in China and marks a significant step in the company’s commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care … [Read more…]
FUJISAWA, Japan & BOSTON–(BUSINESS WIRE)–Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds … [Read more…]
PRINCETON, N.J.–(BUSINESS WIRE)–ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities … [Read more…]
Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years of Experience in Medical Technology and Consumer Healthcare to ZEISS HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today that Gary Rosenblum has been named President and Chief Executive Officer … [Read more…]
SALT LAKE CITY–(BUSINESS WIRE)–#ArtificialIntelligence–Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker™, the company’s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step … [Read more…]
Honor adds to growing list of best employer awards BETHESDA, Md.–(BUSINESS WIRE)–The Washington Post has recognized Aledade, the nation’s largest network of independent value-based primary care, among the best companies to work for in their annual Top Workplaces rankings. Aledade was ranked seventh in The Washington Post’s largest employer category for the District of Columbia … [Read more…]
Research also shows a reversal of the gender pay gap under VBC WESTERVILLE, Ohio–(BUSINESS WIRE)–agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced the publication of new peer-reviewed data examining the impact of gender differences of primary care physicians (PCPs) on patient outcomes, healthcare utilization and … [Read more…]
MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has … [Read more…]
Ono and Vertex have entered into an exclusive collaboration and license agreement for povetacicept in Japan and South Korea Povetacicept is a therapeutic in development for multiple serious B cell-mediated diseases including IgA nephropathy and primary membranous nephropathy Povetacicept is a recombinant fusion protein and a dual antagonist of the BAFF and APRIL cytokines OSAKA, … [Read more…]
